PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

NARecruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

June 27, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Solid Tumor MalignanciesMetastatic CancerBreast CancerColorectal CancerLung CancerBladder Cancer
Interventions
OTHER

Expert Review

Expert reflexive review of next-generation sequencing (NGS) results will be visible in electronic health records (EPIC) for provider review at the University of North Carolina Health System. Expert review will include recommendations for Genome-informed therapy (GIT), identification of available clinical trials, recommendations for additional testing, and/or referrals for genetic counseling.

OTHER

Blood or tissue samples collection.

Blood or tissue samples will be collected for next-generation sequencing (NGS) per standard of care.

OTHER

The Precision Oncology Navigation

The precision oncology navigator will coordinate the collection of blood and /or tissue for next-generation sequencing (NGS), as well as order the NGS if not already ordered. Precision oncology navigator will also assist in NGS financial aid applications, if applicable.

Trial Locations (1)

27599

RECRUITING

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER